Crimson Publishers
Wings to the Research

Review Article

Nicotinamide Riboside and NAD+ Decline: Hype vs. Evidence

Michael AS Guth*

Risk Management Consulting, Oak Ridge, Tennessee, USA

ISSN: 2640-9208



***Corresponding author:** Michael AS Guth, Risk Management Consulting, Oak Ridge, Tennessee, USA

Submission: July 14, 2025

Published: August 07, 2025

Volume 8 - Issue 4

How to cite this article: Michael AS Guth*. Nicotinamide Riboside and NAD+ Decline: Hype vs. Evidence. Nov Tech Nutri Food Sci. 8(4). NTNF. 000692. 2025.
DOI: 10.31031/NTNF.2025.08.000692

Abstract

Nicotinamide riboside (NR), a precursor to Nicotinamide Adenine Dinucleotide (NAD+), has emerged as a popular anti-aging supplement due to its role in cellular energy metabolism and sirtuin activation. Preclinical studies in model organisms demonstrate that NR supplementation can counteract age-related NAD+ decline, improving mitochondrial function, reducing inflammation and extending lifespan. However, human clinical trials reveal only modest benefits-such as enhanced muscle endurance and mild cardiometabolic improvements-with limitations including short study durations, small sample sizes and potential industry bias. While NR appears safe at doses up to 2,000mg/day, concerns persist about its long-term effects and overstated commercial claims. This review critically evaluates the translational gap between animal data and human outcomes, emphasizing the need for rigorous, independent research to validate NR's anti-aging potential.

Keywords: Nicotinamide Riboside (NR) supplementation; NAD+ Decline and aging; NR clinical trials evidence; Anti-aging supplements hype vs. science; NAD+ Boosters and longevity

Introduction

NAD+ biology and age-related decline

Nicotinamide Adenine Dinucleotide (NAD+) is not just an essential coenzyme, but a central mediator of cellular metabolism. It participates in redox reactions that govern energy production, DNA repair mechanisms and the activation of sirtuins-a family of longevity-linked proteins. As a critical substrate for enzymes such as PARP-1 and CD38, NAD+ plays a pivotal role in maintaining genomic stability and regulating inflammatory pathways. The decline of NAD+levels with age, a phenomenon observed across multiple species, including humans, is a pressing issue. This depletion contributes to age-associated cellular dysfunction, including mitochondrial inefficiency, increased oxidative stress and impaired stress resistance. Restoring NAD+ levels has thus emerged as a promising strategy to counteract age-related decline, spurring interest in precursors like Nicotinamide Riboside (NR) that can boost NAD+ biosynthesis.

NR as a NAD+ Booster and review objectives

Among NAD+-enhancing compounds, NR has gained attention due to its efficient conversion to NAD+ via the nicotinamide phosphoribosyl transferase (NAMPT)-dependent salvage pathway, offering potential advantages over traditional precursors like niacin (which can cause flushing) or nicotinamide mononucleotide (NMN) (which faces unresolved questions about bioavailability). Proponents argue that NR supplementation could mitigate age-related NAD+ deficiency, thereby improving metabolic health and longevity. However, while preclinical studies in model organisms show encouraging results, human translational evidence remains limited and often overstated in commercial contexts. This review underscores the necessity for critical evaluation of the current evidence surrounding NR's anti-aging claims. Distinguishing between robust findings and speculative hype is crucial to provide a balanced perspective on its therapeutic potential.

NAD+ Biology and Aging

NAD+ in cellular metabolism and aging

NAD+ serves as a fundamental cofactor in critical biological processes, including energy metabolism through its roles in glycolysis and the tricarboxylic acid (TCA) cycle [1]. Beyond its classical function in redox reactions, NAD+ acts as a substrate for key enzymes such as poly (ADP-ribose) polymerase (PARP-1), which facilitates DNA damage repair [2] and the sirtuin family (SIRT1-7) that regulates cellular stress resistance [3]. These multifaceted roles position NAD+ as a central regulator of cellular homeostasis. Studies demonstrate a 50% reduction in NAD+ levels by middle age in humans [4] and similar patterns in mice [5] correlating with mitochondrial dysfunction and diminished stress resilience [6].

Therapeutic potential of NAD+ restoration

NAD+ restoration strategies show promise for enhancing mitophagy and reducing inflammation [7]. Animal studies demonstrate lifespan extension in yeast and mice with NAD+ boosters like NR [8]. Human trials show modest biomarker improvements [9] though longevity claims remain unproven [10]. The mechanisms of NAD+ precursors continue to be an active area of research [11].

Nicotinamide Riboside Mechanisms of Action and Bioavailability

NR serves as a NAD+ precursor through its conversion to NMN, ultimately boosting intracellular NAD+ levels [12,13]. Compared to traditional NAD+ precursors like niacin (vitamin B3), NR demonstrates superior bioavailability and avoids the flushing response associated with niacin supplementation due to its distinct phosphorylation pathway [14,15]. However, the relative efficiency of NR versus NMN remains debated-while some studies suggest NR's smaller molecular size enhances gastrointestinal absorption [14], others indicate NMN may bypass rate-limiting steps in NAD+ biosynthesis [16]. Recent research has identified the existence of specific NMN transporters (Slc12a8) in mammalian tissues that could potentially give NMN an absorption advantage [17], though human clinical trials comparing the two precursors remain limited. The ongoing controversy stems partly from differing methodologies in bioavailability assessments and the rapid metabolism of both compounds in circulation [14].

Preclinical Evidence

NR supplementation has garnered considerable attention in preclinical studies, revealing potential benefits across various model organisms. Notably, a pivotal 2016 Cell Metabolism study demonstrated that NR administration in aged mice not only extends lifespan but also enhances health span markers, improving mitochondrial function, reducing inflammation and boosting neuromuscular coordination [8]. Building on these findings, subsequent investigations substantiated that NR effectively elevates NAD+ levels in multiple tissues. This increase facilitates mitochondrial biogenesis through activation of sirtuins (SIRT1 and SIRT3) and the metabolic regulator PGC-1α [18]. Further supporting its metabolic role, NR alleviates age-related decline in mice, countering insulin resistance and hepatic steatosis induced by high-fat diets [13]. The benefits of NR extend beyond mammals. In Caenorhabditis elegans, NR supplementation enhances stress resistance, reduces protein aggregation and extends lifespan-effects mediated by the SIRT1 homolog SIR-2.1 [19]. Collectively, these cross-species findings suggest NR's potential to mitigate age-related physiological decline, though translational implications for humans remain unclear. Notably, while NR indirectly activates SIRT1 via NAD+ elevation, its mechanism differs from direct activators like resveratrol. Preclinical evidence suggests NR's sustained NAD+ boosting may offer longer-lasting SIRT1 activation compared to polyphenols [20,10]. However, the absence of head-to-head human trials leaves this advantage unconfirmed.

Human Clinical Trials of Nicotinamide Riboside Supplementation

Clinical trials on NR supplementation in humans have produced mixed but promising results. A 2020 Nature Communications study demonstrated that older adults (aged 60-80) taking 1,000mg/day of NR for six weeks showed improved muscular endurance, elevated NAD+ levels and reduced inflammation compared to placebo [21]. Smaller trials have also explored NR's cardiometabolic effects, with one study reporting modest reductions in blood pressure and arterial stiffness [22] and another noting improved lipid profiles in obese participants [23]. However, these benefits were often mild and inconsistent across studies, leaving their clinical significance unclear. Despite encouraging findings, current research faces notable limitations. Most trials are short-term (< 6 months), industry-funded (e.g., by ChromaDex) [24] and lack independent replication-factors that raise concerns about bias and generalizability [10]. Crucially, while preclinical work links NR to longevity in animals [8], human trials rely on surrogate markers (e.g., NAD+ levels, inflammation) rather than direct health span or lifespan outcomes [25]. Future studies should prioritize longer durations, diverse populations and rigorous independent validation to clarify NR's potential in aging humans.

The Hype Problem

The hype surrounding NAD+ precursors

The commercialization of NR and NMN as anti-aging supplements has been significantly amplified by celebrity endorsements and high-profile researchers like David Sinclair, who publicly advocates for NMN use [26]. This visibility has fueled direct-to-consumer marketing campaigns that often overstate the scientific evidence, with products frequently labeled as "longevity miracles" despite limited human data [10]. While preclinical studies in mice show promising results-including improved mitochondrial function and extended lifespan [8] these findings have not been replicated in human trials. The disconnect between animal models and clinical outcomes highlights a critical gap in translation, as no study has demonstrated that NR or NMN extends lifespan in humans [27].

Marketing vs reality

The supplement industry capitalizes on the compelling mouse data to market NR and NMN as revolutionary anti-aging solutions, often omitting key limitations [24]. For example, while small human trials report modest improvements in NAD+ levels in older adults [22], these effects are far from the dramatic lifespan extension seen in rodents. Furthermore, many clinical trials raise concerns about bias in study design and interpretation [9]. The ongoing discrepancy between hype and evidence underscores the need for rigorous, independent research to clarify whether these supplements deliver meaningful benefits for human aging or simply exploit consumer optimism [10].

Safety and Unknowns

Safety profile and known adverse effects

Clinical studies demonstrate that NR is well-tolerated in humans at doses up to 2,000mg/day, with the most common adverse effects being mild gastrointestinal symptoms (e.g., nausea) and occasional flushing, occurring in <10% of participants [24,9]. These effects are dose-dependent and typically resolve without intervention. A 12-month randomized trial of NR (1,000mg/day) in older adults found no clinically significant changes in liver or kidney function markers, supporting its safety for chronic use [28]. However, most trials have excluded immunocompromised individuals and cancer patients, leaving safety in these populations uncertain [10]. While NR's safety profile is increasingly established, its mechanistic effects in humans require further clarification. Clinical trials using NR doses up to 2,000mg/day demonstrate dose-dependent increases in NAD+ [24], but direct measurements of plasma SIRT1 levels and their persistence remain understudied. Future work should quantify SIRT1 activity kinetics post-NR supplementation.

Theoretical risks and quality control challenges

Preclinical research suggests potential risks requiring further study. A 2022 study in Nature reported that NAD+ augmentation accelerated tumor progression in mouse models of lymphoma and breast cancer, possibly by enhancing cancer cell metabolism [29]. While human relevance remains unclear, this warrants caution in individuals with cancer histories. Additionally, independent analyses of commercial NR/NMN supplements reveal significant quality issues, including mislabeled dosages (e.g., 30-70% less active ingredient than claimed) and contamination with nicotinamide [20]. Unlike pharmaceuticals, these supplements face no mandatory purity testing, exposing consumers to unpredictable risks [30].

Conclusion

The current body of research on Nicotinamide Riboside (NR) as a strategy to counteract age-related NAD+ decline presents both promise and persistent uncertainties. While preclinical studies in model organisms demonstrate compelling benefits-including enhanced mitochondrial function, reduced inflammation and extended lifespan mediated through NAD+-dependent pathways-the translation to human applications remains challenging. Clinical trials to date have revealed only modest improvements in biomarkers and metabolic health, with limitations including short durations, small sample sizes and potential industry bias complicating interpretation. Beyond questions of efficacy, safety considerations merit attention. Although NR appears well-tolerated at doses up to 2,000mg/day, concerns persist regarding long-term use, particularly in populations with cancer histories given preclinical evidence that NAD+ augmentation may accelerate tumor progression. This safety profile exists in stark contrast to the supplement industry's hyperbolic claims, which frequently outpace the available clinical evidence. To resolve these uncertainties, future research must prioritize large-scale, long-term trials with independent oversight, focusing on clinically meaningful endpoints like health span and disease incidence rather than surrogate markers. Particularly relevant to these clinical questions is NR's potential to activate SIRT1, which may offer dual benefits for both aging and metabolic diseases through mitochondrial enhancement and anti-inflammatory effects [11]. However, whether NR provides superior SIRT1 activation compared to other interventions remains an open question requiring direct comparative studies. Until such evidence emerges, NR's position in the anti-aging arsenal remains promising but unproven.

References

1. Cantó C, Menzies KJ, Auwerx J (2015) NAD+ metabolism and the control of energy homeostasis. Molecular Cell 57(2): 335-346.
2. Bai P, Canto C, Oudart H (2011) PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metabolism 13(4): 461-468.
3. Imai S, Guarente L (2014) NAD+ and sirtuins in aging and disease. Trends in Cell Biology 24(8): 464-471.
4. Zhu XH, Lu M, Lee BY (2015) *In-vivo* NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proceedings of the National Academy of Sciences 112(9): 2876-2881.
5. Gomes AP, Price NL, Ling AJ et al (2013) Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155(7): 1624-1638.
6. Fang EF, Scheibye Knudsen M, Chua KF (2017) Nuclear DNA damage signalling to mitochondria in ageing. Nature Reviews Molecular Cell Biology 18(5): 308-321.
7. Fang EF, Kassahun H, Croteau DL (2016) NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metabolism 24(4): 566-581.
8. Zhang H, Ryu D, Wu Y (2016) NAD^+ replenishment improves lifespan and healthspan in ataxia telangiectasia models. Cell Metabolism, 24(6): 795-806.
9. Dollerup OL, Christensen B, Svart M (2018) A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity and lipid-mobilizing effects. American Journal of Clinical Nutrition 108(2): 343-353.
10. Rajman L, Chwalek K, Sinclair DA (2018) NAD+-boosting molecules in aging. Cell Metabolism 27(3): 529-547.
11. Yusri K, Jose S, Vermeulen KS (2025) The role of NAD+ metabolism and its modulation of mitochondria in aging and disease. NPJ Metab Health Dis 3(1): 26.

12. Belenky P, Racette FG, Bogan KL (2007) Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell 129(3): 473-484.

13. Trammell SA, Schmidt MS, Weidemann BJ (2016) Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications 7: 12948.

14. Ratajczak J, Joffraud M, Trammell SA (2016) NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nature Communications 7: 13103.

15. Airhart SE, Shireman LM, Risler LJ (2017) An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement Nicotinamide Riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One 12(12): e0186459.

16. Yoshino J, Baur JA, Imai S (2018) Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 362(6416): 770-775.

17. Grozio A, Mills KF, Yoshino J (2019) Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism 1(1): 47-57.

18. Cantó C, Houtkooper RH, Pirinen E (2012) The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metabolism 15(6): 838-847.

19. Mouchiroud L, Houtkooper RH, Moullan N (2013) The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 154(2): 430-441.

20. Baur JA (2021) Variability in commercial nicotinamide riboside supplements. JAMA Network Open 4(6): e2112576.

21. Dollerup OL, Chubanava S, Agerholm M (2020) A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in older adults with reduced muscle endurance. Nature Communications 11(1): 4916.

22. Martens CR, Denman BA, Mazzo MR (2018) Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. American Journal of Clinical Nutrition 108(2): 343-353.

23. Trammell SA, Weidemann BJ, Chadda A (2017) Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. American Journal of Clinical Nutrition 106(3): 767-776.

24. Conze D, Brenner C, Kruger CL (2019) Safety and metabolism of long-term administration of NIAGEN (Nicotinamide Riboside Chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports 9(1): 9772.

25. Verdin E (2015) NAD+ in aging, metabolism, and neurodegeneration. Science 350(6265): 1208-1213.

26. Sinclair DA, LaPlante M (2019) Lifespan: Why we age-and why we don't have to. Atria Books.

27. Brenner C (2020) NAD+ metabolism and the aging immune system. Trends in Pharmacological Sciences 41(10): 709-712.

28. Martens CR (2020) One-year NR supplementation in older adults. Nature Aging 1(3): 266-275.

29. Navas LE (2022) NAD+ depletion is a therapeutic target in cancer. Nature 602(7895): 84-91.

30. FDA (2022) Dietary Supplement Good Manufacturing Practices (GMPs). Food and Drug Administration, USA.